Inventor · disambiguated record
Peter Hagedorn
Also filed as: HAGEDORN PETER · HAGEDORN PETER H
17 granted patents·29 pending applications·14 citations·filing 2005–2025
89Inventor score
Files withHOFFMANN LA ROCHE18BRISTOL MYERS SQUIBB CO12ROCHE INNOVATION CT COPENHAGEN AS10BOEHRINGER INGELHEIM INT1COHEN IRUN R1
Top patents by PatentIndex Score
46 records- 0195US11359197B2Antisense oligonucleotides targeting alpha-synuclein and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Jun 14, 2022·4 cites·18 claims
- 0290US11279929B2Oligonucleotides for modulating Tau expressionHOFFMANN LA ROCHE·Filed 2019·Granted Mar 22, 2022·3 cites·13 claims
- 0389US11447775B2Antisense oligonucleotides targeting alpha-synuclein and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Sep 20, 2022·3 cites·20 claims
- 0488US2025051777A1Oligonucleotides for modulating tau expressionHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 0588US2025136988A1Antisense oligonucleotides targeting alpha-synuclein and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 0687US10799523B2Tau antisense oligomers and uses thereofHOFFMANN LA ROCHE·Filed 2016·Granted Oct 13, 2020·3 cites·8 claims
- 0784US2024026360A1Oligonucleotides for modulating tau expressionHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 0881US12180478B2Antisense oligonucleotides targeting alpha-synuclein and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Dec 31, 2024·0 cites·20 claims
- 0980US12163131B2Oligonucleotides for modulating Tau expressionHOFFMANN LA ROCHE·Filed 2022·Granted Dec 10, 2024·0 cites·15 claims
- 1075US11753640B2Oligonucleotides for modulating Tau expressionHOFFMANN LA ROCHE·Filed 2020·Granted Sep 12, 2023·0 cites·8 claims
- 1174US11542501B2Antisense oligonucleotides targeting ATXN3HOFFMANN LA ROCHE·Filed 2020·Granted Jan 3, 2023·1 cites·15 claims
- 1274US2025327072A1Antisense oligonucleotides targeting alpha-synuclein and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 1370US2022143064A1Tau antisense oligomers and uses thereofHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 1466US11058767B2CAMK2D antisense oligonucleotides and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jul 13, 2021·0 cites·17 claims
- 1563US12241065B2Antisense oligonucleotides targeting alpha-synuclein and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 4, 2025·0 cites·11 claims
- 1663US2020157546A1Antisense oligonucleotides for modulating htra1 expressionHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 1762US11077132B2Tau antisense oligomers and uses thereofHOFFMANN LA ROCHE·Filed 2016·Granted Aug 3, 2021·0 cites·13 claims
- 1862US11066669B2Oligonucleotides for modulating ATXN2 expressionHOFFMANN LA ROCHE·Filed 2019·Granted Jul 20, 2021·0 cites·23 claims
- 1962US2025188463A1Antisense oligonucleotides targeting alpha-synuclein and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 2062US2022042022A1Antisense oligonucleotides for modulating htra1 expressionHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 2159US2014315740A1Antigen array and diagnostic uses thereofYEDA RES & DEV·Filed 2014·Application pending·0 cites
- 2257US11286485B2Oligonucleotides for modulating ATXN2 expressionHOFFMANN LA ROCHE·Filed 2020·Granted Mar 29, 2022·0 cites·14 claims
- 2357US2021378652A1Camk2d antisense oligonucleotides and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 2456US2020399641A1Antisense oligonucleotides for modulating htra1 expressionHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 2554US2023212572A1Guanosine Analogues for Use in Therapeutics PolynucleotidesROCHE INNOVATION CT COPENHAGEN AS·Filed 2021·Application pending·0 cites
- 2653US11485975B2Oligonucleotides for modulating TMEM106B expressionGENENTECH INC·Filed 2020·Granted Nov 1, 2022·0 cites·30 claims
- 2753US2022213484A1Angptl2 antisense oligonucleotides and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 2851US2019365795A1Oligonucleotides for modulating atxn2 expressionHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 2951US2023193269A1Oligonucleotides for splice modulation of card9BOEHRINGER INGELHEIM INT·Filed 2020·Application pending·0 cites
- 3049US2018016575A1LNA Gapmer Oligonucleotides Comprising Chiral Phosphorothioate LinkagesROCHE INNOVATION CT COPENHAGEN AS·Filed 2015·Application pending·0 cites
- 3149US2021371860A1Oligonucleotides for modulating myh7 expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Application pending·0 cites
- 3249US2005260770A1Antigen array and diagnostic uses thereofCOHEN IRUN R·Filed 2005·Application pending·0 cites
- 3349US2018112217A1Stereospecific Phosphorothioate LNAROCHE INNOVATION CT COPENHAGEN AS·Filed 2015·Application pending·0 cites
- 3448US2021095274A1Oligonucleotides for modulating pias4 expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Application pending·0 cites
- 3548US2021095275A1Oligonucleotides for modulating gsk3b expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Application pending·0 cites
- 3648US2020385714A1Oligonucleotides for modulating fndc3b expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2018·Application pending·0 cites
- 3748US2019055564A1Antisense oligonucleotides for modulating htra1 expressionHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 3848US2021095276A1Oligonucleotides for modulating erc1 expressionROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Application pending·0 cites
- 3947US10519450B2Antisense oligonucleotides for modulating HTRA1 expressionHOFFMANN LA ROCHE·Filed 2017·Granted Dec 31, 2019·0 cites·42 claims
- 4047US2014272998A1Diagnostic microrna profiling in cutaneous t-cell lymphoma (ctcl)RALFKIAER ULRIK·Filed 2012·Application pending·0 cites
- 4145US2022042011A1Antisense oligonucleotides targeting card9HOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 4245US2022119811A1Alpha-synuclein antisense oligonucleotides and uses thereofROCHE INNOVATION CT COPENHAGEN AS·Filed 2019·Application pending·0 cites
- 4343US11761951B2Methods of selecting therapeutic moleculesBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Sep 19, 2023·0 cites·19 claims
- 4441US10815481B2Chiral library screenROCHE INNOVATION CT COPENHAGEN AS·Filed 2015·Granted Oct 27, 2020·0 cites·14 claims
- 4539US2013252839A1Markers of primary graft dysfunctionELHANAN SAHAR·Filed 2011·Application pending·0 cites
- 4639US2018023081A1Lna oligonucleotides with alternating flanksBRISTOL MYERS SQUIBB CO·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Peter Hagedorn files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →